SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Sepracor-Looks very promising -- Ignore unavailable to you. Want to Upgrade?

To: rkrw who wrote (7341)2/2/2004 4:44:12 PM
From: Sidney Street  Respond to of 10280
 
Interesting to see David Saks quoted; before he started his fund he covered SEPR at Gruntal. I wonder how much, if any, SEPR he holds in his fund.



To: rkrw who wrote (7341)2/4/2004 7:58:51 PM
From: Sleepman  Read Replies (1) | Respond to of 10280
 
It is a different class of drug, and they may compete for the limited dollars for treatment per patient, but really they are complementary.
Spiriva is a longer acting medicine like Atrovent.
Currently, Atrovent and albuterol are marketed by Boehringer as Combivent. This is used four times daily.
In the longer run, I see Boehringer teaming up with a long acting beta agonist like arfometerol for a similar once daily product.


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News